Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | NAMPT | P43490 | 12/20 | 0.37 |
| ▸ | GCG | P01275 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | F2RL1 | P55085 | 2/20 | 0.33 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13554484 | 0.91 | NAMPT (0.43) | NPC1RAB9ANAMPTGCG | |
| SCHEMBL3399589 | 0.90 | GCG (0.43) | NPC1RAB9ANAMPTGCG | |
| SCHEMBL719151 | 0.87 | MEN1 (0.45) | NPC1RAB9ANAMPTGCG | |
| SCHEMBL718372 | 0.85 | RCE1 (0.39) | NPC1RAB9AF2RL1F2RL3 | |
| SCHEMBL3402253 | 0.80 | TEAD4 (0.35) | NPC1RAB9AF2RL1F2RL3 | |
| SCHEMBL3401435 | 0.79 | GCG (0.45) | NPC1RAB9AGCG | |
| SCHEMBL720285 | 0.78 | GCG (0.48) | GCG | |
| SCHEMBL721199 | 0.78 | NPC1 (0.48) | NPC1RAB9AGCG | |
| SCHEMBL719119 | 0.77 | KMT2A (0.33) | — | |
| SCHEMBL721727 | 0.77 | NPC1 (0.47) | NPC1RAB9AGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | NPC1 902/4885RAB9A 2454/4885NAMPT 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.